Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dong-A PharmTech to launch Zydena in Russia

This article was originally published in Scrip

Executive Summary

Russia's health ministry has approved Dong-A PharmTech's tablet for erectile dysfunction (ED) Zydena (udenafil). Valenta Pharmaceuticals (formerly Otechestvennie Lekarstva), its local partner, is expected to launch the product in the fourth quarter of this year. Zydena will compete with Pfizer's Viagra (sildenafil citrate) and Lilly's Cialis (tadalafil), but is expected to gain a large share of the market for ED products because of its long action and rare side-effects, Dong-A PharmTech says. Dong-A PharmTech is a South Korean company focusing on the development and commercialisation of udenafil and other drug candidates worldwide. It launched Zydena in Korea in 2005 and captured 24% of the country's ED market within two years. The product is in clinical trials in the US for erectile dysfunction, and it is planning development programmes for other indications such as benign prostatic hyperplasia and pulmonary hypertension.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000964

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel